Our Take
This is a clinical reassurance masked as a detection advance: most people with detectable viral load on treatment aren't failing therapy, they're shedding dead virus from old infected cells.
Why it matters
Patients and clinicians currently treat detectable viral RNA as a treatment failure signal, triggering medication switches, extra visits, and psychological distress. Knowing the virus is already dead changes the clinical decision entirely.
Do this week
HIV clinic leaders: discuss CLAWS assay adoption with your lab director before Q2 2025 so you can begin reclassifying NSV cases and reducing unnecessary treatment changes.
Johns Hopkins identifies defective RNA as the driver of persistent detectable HIV
Researchers at Johns Hopkins University School of Medicine studied 52 people living with HIV who had detectable viral loads despite years of antiretroviral therapy (ART) and perfect treatment adherence. The finding: approximately 95% of detectable HIV-1 RNA in these patients consisted of defective, non-infectious copies (company-reported via Nature Communications publication).
The defects were concentrated in the 5'-leader region of the viral RNA, a section normally responsible for orchestrating viral replication. When mutated or deleted, this region prevents the virus from producing infectious particles, though the defective RNA itself remains detectable in blood plasma.
The team developed a diagnostic tool called CLAWS (Capturing 5′ Leader Anomalies Without Sequencing), a digital PCR assay that distinguishes intact infectious RNA from defective copies. The method is cost-effective and designed for routine use in HIV clinics and cure research settings.
The cohort included 52 participants, predominantly white men ages 58-68, treated in the United States, Canada, and Denmark, with samples collected between 2021 and 2025. In the primary cohort of 31 participants and a validation cohort of 20 additional participants, defective proviruses accounted for a median of 95% of plasma HIV-1 RNA.
Why this matters for patients and treatment decisions
Nonsuppressible viremia (NSV), defined as detectable viral load despite long-term suppressive therapy, occurs in fewer than 1% of people on ART. However, when it occurs, it triggers clinical concern for virologic failure, transmission risk, and ongoing immune activation. Patients report significant anxiety about whether their medication is working and whether they can transmit the virus to partners.
The Johns Hopkins findings suggest that most of these cases involve no actual treatment failure. The defective RNA is released from a small number of long-infected T cells that persist despite ART, but the virus itself cannot establish new infections. In the words of Francesco Simonetti, the study's senior author, "These defective proviruses cannot infect new cells, but they are still clinically relevant" in terms of the diagnostic and psychological burden they create.
The practical implications are immediate: patients with NSV driven by defective RNA may not require additional medications, may not be at significant transmission risk, and may be eligible for elective surgeries, organ transplants, or clinical trials without the barrier of detectable virus. Clinicians can use CLAWS to confirm the source of detectable RNA before modifying treatment regimens.
What HIV programs should do now
Implement CLAWS assay testing for all NSV cases before adjusting antiretroviral regimens. This single step can eliminate unnecessary drug switches, reduce clinic visits and associated costs, and remove a major source of patient anxiety.
Educate patients on the distinction between defective and infectious RNA. Many people living with HIV have been taught to view any detectable viral load as a treatment failure; clinical teams should clarify that defective RNA, while visible on standard tests, does not represent virologic failure or transmission risk.
Document baseline CLAWS results in the medical record so that longitudinal trends can be tracked. Understanding which patients generate persistent defective RNA from stable cell clones versus those with true virologic breakthrough will inform long-term monitoring strategies and cure research protocols.